Sentimag® Localization Platform
One platform delivering wire-free localization and radiation-free SLNB.
Enabling radiation-free sentinel lymph node biopsy
Magtrace® is simple to store and handle, improving workflow efficiency compared with radioactive tracers.
Magtrace® has a 99% detection rate regardless of when it's injected - closely comparable with radioisotope and blue dye.
Unlike blue dye, Magtrace® has no reported cases of anaphylaxis in over 60,000 patients to date, allowing greater confidence in your patient’s health.
The Magtrace® can be injected days or minutes ahead of surgery. This offers unrivalled flexibility in scheduling. It can be timed to coincide with a planned hospital visit or when in the operating room under anesthesia, giving you, the clinician, ultimate control.
Magtrace® Animation
Magtrace® SLNB with Magseed® and Targeted Axillary Dissection
Is Magtrace® composed of tiny magnets?
No, the Magtrace® tracer contains many tiny organically coated iron oxide particles that become temporarily magnetized when the Sentimag® probe is near. This facilitates the system’s ability to perform precision localization procedures.
How far in advance of surgery can the Magtrace® tracer be injected?
The Magtrace® tracer can be injected days or as little as 20 minutes before surgery.
Why should my facility consider radiation-free, blue dye-free tracer for Sentinel Lymph Node Biopsy (SLNB)?
The Magtrace® tracer allows your facility to decouple nuclear medicine and surgery. Radiologists can inject Magtrace® when it’s convenient, and the patient can show up directly to surgical prep the morning of the procedure rather than having to stop at nuclear medicine first. Alternatively, surgeons can also choose to inject Magtrace® up to 20 minutes before starting surgery, saving the patient from the pain of an added injection. Magtrace® also enables surgeons to avoid potential risks associated with traditional blue dye such as anaphylaxis and skin necrosis.
What is Delayed Sentinel Lymph Node Biopsy (dSLNB)?
dSLNB is an exciting new procedure that is performed by injecting the Magtrace tracer in patients with a lower likelihood of having invasive breast cancer. The patient has their mastectomy performed, but does not have a SLNB completed that day. Pathology determines if the patient has invasive or noninvasive cancer in the breast. If non invasive, the patient does not need additional axillary surgery. If it is invasive cancer, the patient may return to surgery for a SLNB. This is a more advanced procedure performed by surgeons familiar with the Sentimag® localization system.
One platform delivering wire-free localization and radiation-free SLNB.
A radiation-free, precision 1x5mm marker that becomes detectable when temporarily magnetized by the Sentimag® probe.
When you need to identify the finest details, in the widest range of specimens, in the shortest possible time.
HydroMARK’s exclusive hydrogel technology provides clinicians with unmatched long-term ultrasound visibility.
© 2021 Devicor Medical Products, Inc., part of Leica Biosystems.
